State Street Corp Acquires 58,838 Shares of INmune Bio, Inc. (NASDAQ:INMB)

State Street Corp boosted its holdings in shares of INmune Bio, Inc. (NASDAQ:INMB) by 35.1% in the third quarter, Holdings Channel reports. The firm owned 226,428 shares of the company’s stock after purchasing an additional 58,838 shares during the quarter. State Street Corp’s holdings in INmune Bio were worth $1,220,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. CVI Holdings LLC acquired a new position in INmune Bio during the second quarter worth $5,260,000. Praetorian PR LLC boosted its stake in shares of INmune Bio by 61.0% in the 3rd quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock valued at $4,209,000 after purchasing an additional 295,800 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of INmune Bio by 332.1% in the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after purchasing an additional 89,091 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of INmune Bio by 124.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after purchasing an additional 32,511 shares during the last quarter. Finally, Rhumbline Advisers bought a new position in INmune Bio during the 2nd quarter valued at about $121,000. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Stock Up 5.6 %

Shares of NASDAQ INMB opened at $4.93 on Friday. INmune Bio, Inc. has a 12-month low of $4.32 and a 12-month high of $14.74. The firm’s 50-day simple moving average is $5.19 and its 200 day simple moving average is $6.25. The company has a market cap of $109.31 million, a price-to-earnings ratio of -2.26 and a beta of 1.79.

INmune Bio (NASDAQ:INMB) last announced its earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative return on equity of 117.48% and a negative net margin of 26,333.59%. During the same quarter in the prior year, the company earned ($0.48) earnings per share. On average, equities analysts expect that INmune Bio, Inc. will post -2.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on INMB shares. Raymond James initiated coverage on shares of INmune Bio in a research note on Friday, September 27th. They set an “outperform” rating and a $18.00 price objective on the stock. Alliance Global Partners initiated coverage on INmune Bio in a report on Monday, October 21st. They issued a “buy” rating and a $20.00 target price on the stock.

INmune Bio Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.